DE69727833D1 - Membraneinbau von texaphyrinen - Google Patents

Membraneinbau von texaphyrinen

Info

Publication number
DE69727833D1
DE69727833D1 DE69727833T DE69727833T DE69727833D1 DE 69727833 D1 DE69727833 D1 DE 69727833D1 DE 69727833 T DE69727833 T DE 69727833T DE 69727833 T DE69727833 T DE 69727833T DE 69727833 D1 DE69727833 D1 DE 69727833D1
Authority
DE
Germany
Prior art keywords
texaphyrin
molecule conjugate
lipophilic molecule
loaded
cells loaded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69727833T
Other languages
English (en)
Other versions
DE69727833T2 (de
Inventor
W Young
Meredith Wright
L Sessler
D Mody
Darren Magda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
University of Texas System
Original Assignee
Pharmacyclics LLC
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC, University of Texas System filed Critical Pharmacyclics LLC
Publication of DE69727833D1 publication Critical patent/DE69727833D1/de
Application granted granted Critical
Publication of DE69727833T2 publication Critical patent/DE69727833T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—3D [Three Dimensional] image rendering
    • G06T15/10—Geometric effects
    • G06T15/20—Perspective computation
    • G06T15/205—Image-based rendering
DE1997627833 1996-06-04 1997-06-04 Membraneinbau von texaphyrinen Expired - Fee Related DE69727833T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65794796A 1996-06-04 1996-06-04
US657947 1996-06-04
PCT/US1997/009501 WO1997046262A2 (en) 1996-06-04 1997-06-04 Membrane incorporation of texaphyrins

Publications (2)

Publication Number Publication Date
DE69727833D1 true DE69727833D1 (de) 2004-04-01
DE69727833T2 DE69727833T2 (de) 2005-01-13

Family

ID=24639282

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1997627833 Expired - Fee Related DE69727833T2 (de) 1996-06-04 1997-06-04 Membraneinbau von texaphyrinen

Country Status (12)

Country Link
EP (1) EP0954336B1 (de)
JP (1) JP2000512279A (de)
CN (1) CN1225591A (de)
AT (1) ATE260121T1 (de)
AU (1) AU727138B2 (de)
BR (1) BR9710685A (de)
CA (1) CA2257225A1 (de)
DE (1) DE69727833T2 (de)
IL (1) IL127315A (de)
NO (1) NO985645L (de)
NZ (1) NZ333072A (de)
WO (1) WO1997046262A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
US6375930B2 (en) 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
CA2278937A1 (en) * 1996-12-11 1998-06-18 Pharmacyclics, Inc. Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy
US6183727B1 (en) 1998-05-19 2001-02-06 Arizona Board Of Regents Use of long-wavelength electromagnetic radiation and photoprotective tumor localizing agents for diagnosis
JP2002534218A (ja) * 1999-01-15 2002-10-15 ライト サイエンシーズ コーポレイション 非侵襲性の脈管療法
EP1206288B1 (de) * 1999-08-02 2007-01-10 The Regents Of The University Of Michigan Zielgerichtete fiberlose radiative effektoren
US6944493B2 (en) 1999-09-10 2005-09-13 Akora, Inc. Indocyanine green (ICG) compositions and related methods of use
AU7106400A (en) * 1999-09-10 2001-04-10 Akorn, Inc. Fluorescent dye angiography and dye-enhanced photocoagulation
US6351663B1 (en) 1999-09-10 2002-02-26 Akorn, Inc. Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US6319273B1 (en) * 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
US7112671B2 (en) 2000-08-30 2006-09-26 Pharmacyclics, Inc. Non-symmetric tripyrranes in the synthesis of novel macrocycles
US7449454B2 (en) 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
EP1684723A4 (de) * 2003-11-21 2007-06-20 Fujifilm Corp Kontrastmittel mit liposomen mit hydrophober chelierverbindung
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
CN107735402B (zh) * 2015-04-17 2021-03-26 大学健康网络 德克萨卟啉-磷脂缀合物及其制备方法
CN111265674A (zh) * 2020-03-24 2020-06-12 浙江大学医学院附属第四医院(浙江省义乌医院、浙江大学医学院附属第四医院医共体) 一种造影剂、造影剂的制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5120411A (en) * 1989-12-21 1992-06-09 Board Of Regents, The University Of Texas System Photodynamic activity of sapphyrins
US5591422A (en) * 1995-06-02 1997-01-07 Pharmacyclics, Inc. Texaphyrin complexes having improved functionalization

Also Published As

Publication number Publication date
WO1997046262A3 (en) 1998-03-12
EP0954336A2 (de) 1999-11-10
EP0954336B1 (de) 2004-02-25
AU3226497A (en) 1998-01-05
ATE260121T1 (de) 2004-03-15
NO985645L (no) 1999-02-03
WO1997046262A2 (en) 1997-12-11
BR9710685A (pt) 2000-01-11
AU727138B2 (en) 2000-12-07
NO985645D0 (no) 1998-12-03
JP2000512279A (ja) 2000-09-19
CA2257225A1 (en) 1997-12-11
DE69727833T2 (de) 2005-01-13
IL127315A0 (en) 1999-09-22
IL127315A (en) 2003-05-29
NZ333072A (en) 2000-06-23
CN1225591A (zh) 1999-08-11

Similar Documents

Publication Publication Date Title
DE69727833D1 (de) Membraneinbau von texaphyrinen
Kiley et al. Removal of blood ammonia by hemodialysis.
Birgegård et al. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation
CA2285203A1 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
DE3650572D1 (de) Kontrastmittel zur darstellung des leber-gallensystems mittels nmr-kontrastmittel
ATE99544T1 (de) Liposomale radiologische kontrastmittel.
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
Geel Development-related changes of triiodothyronine binding to brain cytosol receptors
JPH05501856A (ja) 脳及び筋肉組織傷害による浮腫の治療剤
Green et al. Human central nervous system and plasma pharmacology of mitoxantrone
Stewart et al. The treatment of patients with interstitial cystitis, with special reference to intravesical DMSO
Ley et al. Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: neurobehavior, histopathology, and pharmacokinetics
Hjelm et al. BIOCHEMICAL EFFECTS OF AROMATIC AMINES: II. CYANOSIS, METHAEMOGLOBINAEMIA AND HEINZ‐BODY FORMATION INDUCED BY A LOCAL ANAESTHETIC AGENT (PRILOCAINE)
Duray et al. Demonstration of cutaneous doxorubicin extravasation by rhodamine‐filtered fluorescence microscopy
Kuhn Autoradiographic evidence for binding of3H-flunitrazepam (Rohypnol®) to melanin granules in the cat eye
WO2007122280A1 (es) Uso del factor de crecimiento de hígado (lgf) como regenerador tisular pleiotrópico
De Dobbeleer et al. In vitro acantholysis induced by D‐penicillamine, captopril, and piroxicam on dead de‐epidermized dermis
RU2166924C1 (ru) Способ обогащения крови стволовыми кроветворными клетками
RU2192817C2 (ru) Способ лечения частичной атрофии зрительного нерва
RU2161036C2 (ru) Способ лечения хронических диффузных заболеваний печени
McGuire et al. In vivo diffusion of lidocaine through tissue expanders
Nuernberg et al. Anti-inflammatory effects and disposition of S-and R-flurbiprofen in the rat
Piller et al. The effect of coumarin (5, 6 benzo-α-pyrone) on elicited members of the mononuclear system in dogs with chronic secondary lymphedema
Ushiyama et al. Physiological Effects of Continuous Whole-Body Exposure to Extremely Low Frequency Electromagnetic Fields With or Without Transient Magnetic Fields on Cerebral Microcirculation in Mice With Brain Tumors
Abdollahi et al. New approach to the efficacy of oximes in the management of acute organophosphates poisoning

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee